A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

(2020) Haifa Kathrin Al‐Ali et al.   BRITISH JOURNAL OF HAEMATOLOGY

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

(2020) Jean-Jacques Kiladjian et al.   Lancet Haematology

Momelotinib for the treatment of myelofibrosis

(2019) Li Xu et al.   EXPERT OPINION ON PHARMACOTHERAPY

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

(2018) Claire N Harrison et al.   Lancet Haematology

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

(2017) Ruben A. Mesa et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

(2017) Srdan Verstovsek et al.   Journal of Hematology & Oncology

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis

(2017) A Pardanani et al.   LEUKEMIA

Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management

(2016) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms

(2016) Elisa Rumi et al.   BLOOD

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

(2016) Vikas Gupta et al.   HAEMATOLOGICA

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

(2016) Ruben Mesa et al.   Journal of the National Comprehensive Cancer Network

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

(2016) Vikas Gupta et al.   HAEMATOLOGICA

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

(2013) A Pardanani et al.   LEUKEMIA

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular aspects of myeloproliferative neoplasms

(2010) François Delhommeau et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment

(2008) Omar I. Abdel-Wahab et al.   Annual Review of Medicine

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD